US 20030170838A1
· Mishra et al.
· 2003
[cited by applicant]
US 20130156849A1
· De Fougerolles et al.
· 2013
[cited by applicant]
US 20180311343A1
· Huang et al.
· 2018
[cited by applicant]
US 20200376142A1
· Micol
· 2020
[cited by applicant]
WO WO2013090648A1
· 2013
[cited by applicant]
WO WO2013126712A1
· 2013
[cited by applicant]
WO WO2015058069A1
· 2015
[cited by applicant]
WO WO2015070060A1
· 2015
[cited by applicant]
WO WO2016011306A2
· 2016
[cited by applicant]
WO WO2016100812A1
· 2016
[cited by applicant]
WO WO2017062513A1
· 2017
[cited by applicant]
WO WO2017132552A1
· 2017
[cited by applicant]
WO WO2018115527A2
· 2018
[cited by applicant]
WO WO2019158955A1
· 2019
[cited by applicant]
Criscitiello et al. Breast Care 7:262-266 (Year: 2012).
[cited by examiner]
JP Office Action in Japanese Application No. 2020-536493, dated Aug. 16, 2022, 9 pages (with English translation).
[cited by applicant]
Ruiz et al., “MicroRNAs and oncolytic viruses”, Current Opinion in Virology, Apr. 2015, 13:40-48.
[cited by applicant]
Wroblewska et al., “Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery”. Nature Biotechnology, Aug. 2015, 33(8): 839-841.
[cited by applicant]
Aghi et al., “Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16,” Oncogene, 27: 4249-4254 (2008).
[cited by applicant]
Aref et al., “Measles to the Rescue: A Review of Oncolytic Measles Virus,” Viruses, 8: 294 (2016).
[cited by applicant]
Baker et al., “Designer Oncolytic Adenovirus: Coming of Age,” Cancers, 10: 201 (2018).
[cited by applicant]
Baltimore, “Expression of Animal Virus Genomes,” Bacteriological Reviews, 35(3): 235-241 (1971).
[cited by applicant]
Braconi et al., The role of microRNAs in human liver cancers, Seminars in Oncology, 38(6):752-763 (2011).
[cited by applicant]
Brown et al., “Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications,” Nature Reviews Genetics, 10: 578-585 (2009).
[cited by applicant]
Brun et al., “Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus,” Molecular Therapy, 18(8): 1440-1449 (2010).
[cited by applicant]
Chen et al., “Rapid Discovery of Potent siRNA-Containing Lipid Nanoparticles Enabled by Controlled Microfluidic Formulation,” J. Am. Chem. Soc., 134: 6948-6951 (2012).
[cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B—lineage leukemia effect.” Blood, 101(4): 1637-1644 (2003).
[cited by applicant]
Coppola et al., “Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf,” Oncotarget, 8(15): 25289-25299 (20…
[cited by applicant]
Cotton et al., 142] Receptor-Mediated Transport of DNA into Eukaryotic Cells, Methods in Enzymology, 217: 618-644 (1993).
[cited by applicant]
Edge et al., “A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumorspecific Replication,” Molecular Therapy, 16(8): 1437-1443 (2008).
[cited by applicant]
El Ouaamari et al., “miR-375 Targets 3′ -Phosphoinositide-Dependent Protein Kinase-1 and Regulates Glucose-Induced Biological Responses in Pancreatic ?-Cells,” Diabetes. 57: 2708-2717 (2008).
[cited by applicant]
Felt et al., “Chitosan: A Unique Polysaccharide for Drug Delivery,” Drug Development and Industrial Pharmacy, 24(11): 979-993 (1998).
[cited by applicant]
Fiume et al., “Targeting of antiviral drugs to the liver using glycoprotein carriers,” Advanced Drug Delivery Reviews, 14: 51-65 (1994).
[cited by applicant]
Gao et al., “An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1 3′ untranslated region confers risk for hepatocellular carcinoma,” Carcinogenesis, 30(12):2064-2069 ,2009).
[cited by applicant]
Goldsmith et al., “Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD81 T Cell Response,” J. Exp. Med., 187(3): 341-348 (1998).
[cited by applicant]
Hamad et al., “Demonstration of the Presence of the “Deleted” MIR122 Gene in HepG2 Cells,” PLoS One, 10(3): e0122471 (2015).
[cited by applicant]
Haralambieva et al.. “Engineering Oncolytic Measles Virus to Circumvent the Intracellular Innate Immune Response,” Molecular Therapy. 15(3): 588-597 (2007).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB2019/050454 dated May 8, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/049772 mailed Dec. 19, 2018.
[cited by applicant]
Jena et al., “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor,” Blood, 116(7): 1035-1044 (2010).
[cited by applicant]
Kaczmarek et al., “Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs,” Angew Chem Int Ed Engl., 55(44): 13808-13812 (2016).
[cited by applicant]
Kasuya et al., “Suitability of a US3-inactivated HSV mutant (L1 BR1) as an oncolytic virus for pancreatic cancer therapy,” Cancer Gene Therapy, 14: 533-542 (2007).
[cited by applicant]
Kauffman et al., “Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs,” Nano Lett.. 15: 7300-7306 (2015).
[cited by applicant]
Kutay et al.. “Downregulation of miR-122 in the Rodent and Human Hepatocellular Carcinomas,” J Cell Biochem., 99(3): 671-678 (2006).
[cited by applicant]
Lagos-Quintana et al., “Identification of Tissue-Specific MicroRNAs from Mouse,” Current Biology, 12: 735-739 (2002).
[cited by applicant]
Leopardi et al.. “The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the?virus,” Proc. Natl. Acad. Sci. USA, 94: 7891-7896 (1997).
[cited by applicant]
Liu et al., “ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.” Gene Therapy, 10: 292-303 (2003).
[cited by applicant]
Lohcharoenkal et al., “Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy,” BioMed Research International, vol. 2014, Article ID 180549, 12 pages (2014).
[cited by applicant]
Lui et al., “Patterns of Known and Novel Small RNAs in Human Cervical Cancer,” Cancer Res, 67: 6031-6043 (2007).
[cited by applicant]
Marchini et al., “Oncolytic parvoviruses: from basic virology to clinical applications,” Virology Journal, 12:6 (2015).
[cited by applicant]
Mazzacurati et al., “Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV,” Molecular Therapy, 23(1): 99-107 (2015).
[cited by applicant]
Moffett et al., “Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers,” Nature Communications, 8: Article No. 389 (2017).
[cited by applicant]
Nicholson et al., “Construction and Characterisation of a Functional CD19 Specific Single Chain Fv Fragment fFor Immunotherapy of B Lineage Leukaemia and Lymphoma,” Molecular Immunology, 34(16-17): 1157-1165 (1997).
[cited by applicant]
Nygaard et al., “Identification and analysis of miRNAs in human breast cancer and teratoma samples using deep sequencing,” BMC Medical Genomics, 2:35 (2009).
[cited by applicant]
Park et al., “Treating Cancer with Genetically Engineered T Cells,” Trends Biotechnol., 29(11): 550-557 (2011).
[cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2021/043975, dated Dec. 6, 2021, 13 pages.
[cited by applicant]
Russell et al., “Oncolytic Virotherapy,” Nat. Biotechnol., 30(7): 658-670 (2014).
[cited by applicant]
Singh et al. Indian J Med Res. Oct. 2012; 136(4): 571-584 (Year: 2012).
[cited by applicant]
Song et al., “Expression levels of microRNA-375 in pancreatic cancer,” Biomedical Reports, 1: 393-398 (2013).
[cited by applicant]
Vigil et al., “Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus,” Cancer Res, 67(17): 8285-8292 (2007).
[cited by applicant]
Wagner et al., “Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis,” Advanced Drug Delivery Reviews, 14: 113-135 (1994).
[cited by applicant]
Watahiki et al., “MicroRNAs Associated with Metastatic Prostate Cancer,” PLoS One 6(9): e24950 (2011).
[cited by applicant]
Wyman et al., “Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries,” PLoS One 4(4): e5311 (2009).
[cited by applicant]
Yu et al., “let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells,” Cell, 131; 1109-1123 (2007).
[cited by applicant]
Zhang et al., “Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome”, Database EMBL, MN908947, Jan. 15, 2020, 15 pages.
[cited by applicant]